Sanofi looks to go to FDA in Q4 as diabetes combo LixiLan hits goal in trial

Sanofi ($SNY) has gotten a bit of positive reinforcement in its efforts to revive its diabetes business in the U.S. Experimental combo med LixiLan has thrown off some promising results, hitting its primary goal in a late-stage trial. The results set it up to file for FDA approval in Q4 of this year and for European approval in 2016's first quarter. Sales have been forecast to reach €770 million by 2020. It will compete in Europe with Novo Nordisk's ($NVO) Xultophy, which won and European approval last year. Sanofi, whose blockbuster Lantus has been squeezed by payers, has projected flat to limited growth in its diabetes biz through 2018. More from FiercePharmaMarketing | And more

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.